SSWM
KNSA icon

Sheets Smith Wealth Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Sheets Smith Wealth Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,162
Closed -$295K – 403
2025
Q4 		$295K Hold
7,162
– – 0.03% 349
2025
Q3 		$278K Buy
+7,162
New +$233K 0.03% 356

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Sheets Smith Wealth Management's KNSA Position: Q1 2026 in Review

Sheets Smith Wealth Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 7,162 shares — an estimated $295K sold.

Sheets Smith Wealth Management first reported a position in KNSA in Q3 2025 and held it in 2 quarters. The position peaked at $295K in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Sheets Smith Wealth Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 7,162 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $295K.
  • Sheets Smith Wealth Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Sheets Smith Wealth Management's Kiniksa Pharmaceuticals position peaked at $295K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Sheets Smith Wealth Management's 13F filing for Q1 2026, filed 16 Apr 2026.